Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Blueprint Medi Cm ST (BPMC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 1,951,000
  • Shares Outstanding, K 39,020
  • Annual Sales, $ 27,770 K
  • Annual Income, $ -72,500 K
  • 36-Month Beta 1.27
  • Price/Sales 67.14
  • Price/Cash Flow 0.00
  • Price/Book 9.68

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.38 +45.43%
on 05/31/17
50.14 -0.28%
on 06/23/17
+11.00 (+28.21%)
since 05/23/17
3-Month
34.38 +45.43%
on 05/31/17
50.14 -0.28%
on 06/23/17
+8.99 (+21.92%)
since 03/23/17
52-Week
17.35 +188.18%
on 06/27/16
50.14 -0.28%
on 06/23/17
+30.47 (+156.02%)
since 06/23/16

Most Recent Stories

More News
Blueprint Medicines Announces New Phase 1 Clinical Data for BLU-285 in Advanced Gastrointestinal Stromal Tumors and Plans to Pursue Expedited Development in Patients with a PDGFRa D842V Mutation

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced new Phase 1 clinical data...

BPMC : 50.00 (+4.62%)
Blueprint Medicines to Present at Upcoming Investor Conferences in June

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and development targeted kinase medicines for patients with genomically defined diseases, today announced its participation in the...

BPMC : 50.00 (+4.62%)
Investor Network: Blueprint Medicines Corp. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 3, 2017 / Blueprint Medicines Corp. (NASDAQ: BPMC) will be discussing their earnings results in their Q1 Earnings Call to be held May 3, 2017 at 8:30 AM Eastern Time.

BPMC : 50.00 (+4.62%)
Blueprint Medicines Reports First Quarter 2017 Financial Results

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today reported financial results and provided...

BPMC : 50.00 (+4.62%)
Blueprint Medicines to Report First Quarter 2017 Financial Results on Wednesday, May 3, 2017

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it will host a live...

BPMC : 50.00 (+4.62%)
Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the closing of its previously...

BPMC : 50.00 (+4.62%)
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the pricing of an underwritten...

BPMC : 50.00 (+4.62%)
Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it has commenced an...

BPMC : 50.00 (+4.62%)
Blueprint Medicines to Present on BLU-285 and BLU-554 at Upcoming Scientific Conferences

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it will present on...

BPMC : 50.00 (+4.62%)
BPMC Crosses Above Average Analyst Target

In recent trading, shares of Blueprint Medicines Corp have crossed above the average analyst 12-month target price of $42.75, changing hands for $43.96/share. When a stock reaches the target an analyst...

BPMC : 50.00 (+4.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Blueprint Medicines Corp is an oncology company which is engaged in developing kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines Corp is based in Cambridge, MA.

See More

Support & Resistance

2nd Resistance Point 51.81
1st Resistance Point 50.91
Last Price 50.00
1st Support Level 48.33
2nd Support Level 46.65

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.